6-K: European Regulatory Authority Adopts a Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss
6-K: Novo Nordisk A/S - Share Repurchase Programme
11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)
11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
SD: Specialized disclosure report
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Once-Weekly and Once-Monthly Mim8 Demonstrate Superior Reduction of Treated Bleeding Episodes Compared to On-Demand and Prior Prophylaxis Treatment in People with Haemophilia a in the Frontier 2 Trial
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Novo Nordisk A/S - Share Repurchase Programme
No Data